billS3101Event Tuesday, November 4, 2025Analyzed

SAFE KIDS Act

Neutral

Summary

The SAFE KIDS Act (S.3101) is an early-stage bill targeting only surrogacy contracts with foreign adversarial nations. It authorizes zero funding and imposes criminal penalties on surrogacy brokers, which are not identifiable as publicly-traded pure-play entities. No publicly traded company faces direct material revenue impact at this time.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.3101 is an early-stage bill with only one sponsor and no companion — negligible passage probability in the near term
  • 2.Zero funding authorized — no revenue opportunity for any company
  • 3.Scope is extremely narrow — only foreign adversarial surrogacy contracts, leaving the vast majority of the surrogacy and fertility market untouched
  • 4.No publicly traded pure-play surrogacy brokers exist to be impacted by the criminal penalties

Market Implications

No market implications for publicly traded securities at this stage. Healthcare and fertility service providers such as Progyny ($PGNY) and CooperCompanies ($COO) remain unaffected due to the bill's narrow focus on surrogacy brokerage with adversarial nations. Monitor for advancement past committee or introduction of a companion bill, which would warrant reassessment.

Full Analysis

  1. What happened and its current status: Senator Rick Scott (R-FL) introduced S.3101, the SAFE KIDS Act, on November 4, 2025. It was read twice and referred to the Senate Judiciary Committee. The bill has only one cosponsor and no companion bill in the House. It remains in early-stage committee referral with no further action recorded as of the current date.

  2. The money trail: The bill authorizes no funding whatsoever. It establishes no grants, tax credits, loans, or procurement programs. Its mechanism is exclusively prohibitory and penal — it invalidates surrogacy agreements with foreign adversarial nationals and creates criminal penalties for brokers who facilitate them. There is no spending or revenue stream for companies to capture.

  3. Structural winners and losers: The bill targets a niche subset of the U.S. surrogacy market — prospective parents from foreign entities of concern as defined by 10 U.S.C. § 4872(f)(2). The explicit scope excludes all domestic surrogacy arrangements and those from non-adversarial nations. No publicly traded pure-play surrogacy brokers exist on U.S. exchanges. Major healthcare and fertility services companies (e.g., Progyny - $PGNY, CooperCompanies - $COO) derive revenue from employer-based fertility benefits and IVF services, which are structurally separate from surrogacy brokerage. The criminal penalties apply to brokers who commercially facilitate invalid agreements, not to physicians, clinics, or broader fertility providers.

  4. Competitive landscape: The surrogacy industry in the U.S. is dominated by private agencies, law firms, and boutiques. The bill would not shift market share to any publicly-traded entity.

  5. Timeline: The bill requires passage through the Senate Judiciary Committee, floor votes in both chambers, and presidential signature to become law. Given single-sponsor status with no House companion and zero enacted actions since referral, legislative momentum is minimal. No timeline for further action can be projected.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →